The Lancet paper:
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
https://www.thelancet.com/journals/lancet/article/PIIS0140-6...